HOMEwww.epgonline.orgDRUGSwww.epgonline.orgDISEASE KNOWLEDGEwww.epgonline.orgGUIDELINESwww.epgonline.orgCLINICAL TRIALSwww.epgonline.orgREGISTERwww.epgonline.orgSEARCH
Members
Why a doctor should
Username/Email

Password ()




EPG on Twitter EPG Online Twitter
EPG Online Blog EPG Online Blog
EPG Online Disease Knowledge Centres Feed Disease Knowledge
Recent UK Drug Updates Drug Updates
EPG Search
Search
Languages

Xylometazoline Nasal Drops overview
For the symptomatic relief of nasal congestion, perennial and allergic rhinitis (including hay fever), sinusitis
banner_pass = 1

Please register to access disease diagnosis, patient management, physician tools.
By viewing the content of this web page you are both confirming your status as a healthcare professional and agreeing to our terms of use.

Change language Current language database: English
 
 
Related DrugsDrug Details
Xylometazoline Nasal Drops
Drug Class Description :

Sympathomimetics (decongestants).

Generic Name :

Generic

Drug description :

Xylometazoline Hydrochloride 0.1% w/v

Presentation :

Nasal drops, solution The product is a clear, colourless solution

Indications :

For the symptomatic relief of nasal congestion, perennial and allergic rhinitis (including hay fever), sinusitis

Adult Dosage :

Adults and elderly (all indications): 2 or 3 drops in each nostril 2 or 3 times daily.

The drops are suitable for children over 12 years of age.

Route of administration: Nasal use

Child Dosage :

Under three months, not recommended; under two years, recommended; under two years, doctor's advice only; over three months, instil one to two drops into each nostril once or twice daily when required. Maximum duration, seven days.

Contra Indications :

Known hypersensitivity to Otrivine.

Patients with trans-sphenoidal hypophysectomy or surgery exposing the dura mater.

Special Precautions :

Patients are advised not to take decongestants for more than seven consecutive days. Otrivine, like other preparations belonging to the same class of active substances, should be used only with caution in patients showing a strong reaction to sympathomimetic agents as evidenced by signs of insomnia, dizziness etc.

  • Do not exceed the recommended dosage
  • Decongestants should not be used for more than seven consecutive days. If symptoms persist consult your doctor
  • If you are pregnant or taking other medicines or are under a doctor's care consult him before using Otrivine
  • The adult drops should not be used for infants or children under 12 years
  • Each Otrivine pack should be used by one person only to prevent any cross infection
  • Some patients who have sensitive nasal passages may feel some local discomfort when applying nasal drops. Other side effects are very rare
  • Keep medicines out of reach of children

Adverse Reactions :

The following side effects have occasionally been encountered: A burning sensation in the nose and throat, local irritation, nausea, headache, and dryness of the nasal mucosa.

Systemic cardiovascular effects have occurred, and this should be kept in mind when giving Otrivine to people with cardiovascular disease

Manufacturer :

Novartis Consumer Health UK Limited

Drug Availability :

GSL

Drug Updated :

25 March 2009

Related Drugs - Local reactants on the nose
Niemann-Pick Type C Alzheimer's disease (AD) is a progressive, neurodegenerative disease which will affect most of us at one point in time, and it’s prevalence increases with age. Opioid and Pain Management - understanding, management, diagnosis and treatment information Cystic Fibrosis
New and updated Drugs
UK Drugs EPG Medical News Feed
Spanish Drugs EPG Medical News Feed
German Drugs EPG Medical News Feed
Norweigan Drugs EPG Medical News Feed
Netherlands Drugs EPG Medical News Feed
Swedish Drugs EPG Medical News Feed
French Drugs EPG French Drugs Feed
Portuguese Drugs EPG Portuguese Drugs Feed
Italian Drugs EPG Italian Drugs Feed

Atopic Dermatitis

Atopic Dermatitis

CONNECT

DISEASE CENTRES Disease Centres feed

AFFILIATE PARTNERS

QUICK SEARCH

GUIDELINES UK Drug Data Feed

DRUG DATA UK Drug Data Feed

REFERENCES